Cerino A, Boender P, La Monica N, Rosa C, Habets W, Mondelli M U
Istituto di Clinica delle Malattie Infettive, I.R.C.C.S. Policlinico San Matteo, University of Pavia, Italy.
J Immunol. 1993 Dec 15;151(12):7005-15.
PBMC from a patient with chronic hepatitis C virus (HCV) infection were immortalized with EBV and plated by limiting dilution. Cultures secreting antibodies reactive in a commercial HCV II generation ELISA, which incorporates Ag derived from the nucleocapsid, NS3, and NS4 regions, were repeatedly cloned in the presence of feeder cells and growth factors. Of 23 initially immunoreactive cultures, only one cloned line, designated B12.F8, secreted HCV nucleoprotein-specific IgG1(kappa), whereas no reaction with recombinant polypeptides derived from NS3, NS4, and NS5 regions were documented. Human mAb (hmAb) B12.F8 was shown to recognize the native HCV nucleoprotein expressed in eukaryotic cells transfected with a core cDNA construct by immunofluorescence. The fine specificity of this hmAb was evaluated using synthetic oligopeptides covering the entire HCV nucleocapsid region. A weak but consistent reactivity was observed by PEPSCAN using a 12-mer encompassing residues 34-45 of the HCV-deduced amino acid sequence. Such weak reactivity is indicative for conformational epitopes and, in concurrence with this assumption, we found that longer peptides from the region containing residues 27-59 were more efficiently recognized and effectively inhibited binding of hmAb B12.F8 to recombinant nucleocapsid protein. Several overlapping immunoreactive fragments from the nucleocapsid region were selected from a random cDNA library consisting of DNase I fragments of recombinant core Ag. Best reactive recombinants were identified within residues 1-78 of the HCV sequence, in agreement with the results obtained using synthetic peptides. Comparative experiments on the fine specificity of sera from HCV-infected patients with anticore antibodies invariably showed recognition of peptides 8-40 and 27-59, as well as recombinant fragments spanning from residues 1 to 73, suggesting that hmAb B12.F8 identifies a major B cell epitope within the immunodominant nucleoprotein amino terminal subregion.
来自一名慢性丙型肝炎病毒(HCV)感染患者的外周血单核细胞(PBMC)用EB病毒进行永生化处理,并通过有限稀释法接种培养。在含有饲养细胞和生长因子的情况下,对在商业化HCV第二代酶联免疫吸附测定(ELISA)中分泌反应性抗体的培养物进行反复克隆,该ELISA使用源自核衣壳、NS3和NS4区域的抗原。在最初的23个免疫反应性培养物中,只有一个克隆系,命名为B12.F8,分泌HCV核蛋白特异性IgG1(κ),而未记录到与源自NS3、NS4和NS5区域的重组多肽发生反应。通过免疫荧光显示,人单克隆抗体(hmAb)B12.F8能够识别用核心cDNA构建体转染的真核细胞中表达的天然HCV核蛋白。使用覆盖整个HCV核衣壳区域的合成寡肽评估了该hmAb的精细特异性。通过肽扫描(PEPSCAN)观察到,使用包含HCV推导氨基酸序列34至45位残基的12聚体时有微弱但一致的反应性。这种微弱的反应性表明存在构象表位,与此假设一致,我们发现来自包含27至59位残基区域的较长肽段能更有效地被识别,并有效抑制hmAb B12.F8与重组核衣壳蛋白的结合。从由重组核心抗原的DNA酶I片段组成的随机cDNA文库中选择了几个来自核衣壳区域的重叠免疫反应性片段。在HCV序列的1至78位残基内鉴定出反应性最强的重组体,这与使用合成肽获得的结果一致。对具有抗核心抗体的HCV感染患者血清的精细特异性进行的比较实验始终显示,能识别肽段8至40和27至59,以及跨越残基1至73的重组片段,这表明hmAb B12.F8识别了免疫显性核蛋白氨基末端亚区域内的一个主要B细胞表位。